India’s Biocon spinning off its R&D division

India's Biocon is following the footsteps of a lineup of the subcontinent's biopharma companies in spinning off its R&D operations into a separate company. Sun, Wockhardt and Ranbaxy have all announced similar plans, which analysts say can help attract investors into the sector. Biocon's Kiran Mazumdar Shaw also said that Biocon is also preparing to establish its own tablet formulation manufacturing facility. That work has been done by a contract manufacturer.

- check out the story from the Economic Times

Suggested Articles

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.